Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the ...
- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...
Tandem Diabetes Care (Nasdaq:TNDM) today announced the rollout of its latest automated insulin delivery system integration.
The US Food and Drug Administration has cleared Abbot's Freestyle Libre 3 system for use by people with diabetes aged 4 years and older. The new system was cleared for use for both iOS and Android ...
If you need to track your glucose daily, you probably want a pain-free option. Besides pricking your finger, there are now wearable devices that are placed on your arm and connect to an app on your ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
The CGM market is an exciting, fast-growing, multibillion-dollar medtech sector, according to our new Medtech Market ...
ABBOTT PARK, Ill. & SAN DIEGO--(BUSINESS WIRE)--Abbott (NYSE: ABT), the global health care company, and Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback